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Significance of lactic acid accumulation after expo-
sure to iodinated contrast media in diabetic pati-
ents receiving metformin
Abdulrahman Al-Moghairi, Ali Almasood, Rahim
Gul, Fadwa Alkhuraisi, Hussein Al-Amri
Background: Metformin is a biguanide oral hypogly-
cemic agent with cardio protective effect. Lactic acidosis
is a rare fatal adverse effect of metformin (0.01–0.15 per
1000 patients). Administration of intravenous iodinated
contrast media during radiologic procedures may lead
to acute decline in renal function (0.1–13%) and subse-
quent lactic acidosis in patients receiving metformin
therapy. No clinical trials tested the extent of lactic acido-
sis in diabetic patients exposed to contrast media.
Objective: This study aimed to investigate the corre-
lation of lactic acid accumulation with clinical outcome in
metformin treated diabetic patients exposed to contrast
media.
Methods: A single-center, prospective single arm
clinical observational trial involved diabetic patients on
metformin therapy undergoing cardiac catheterization.
The study endpoints are drawn from laboratory and clin-
ical outcomes. Patients with acute renal dysfunction or
deterioration were excluded from the study. The patients
were followed at baseline, and 72 h for clinical and labo-
ratory assessment. The primary end point was clinically
significant lactic acidosis.
Results: 156 diabetic patients on metformin were
enrolled in this study with mean age of 61.8 ± 10.4, 84%
were males. Lactic acid, bicarbonate, and pH levels, at
baseline and 72 h were; (1.7 ± 1.2 & 2.1 ± 1.8, p
value = 0.016), (24.4 ± 2.0 & 24.6 ± 3.2, p = 0.7), and
(7.37 ± 0.05 & 7.36 ± 0.06, p = 0.44), respectively. All
patients were clinically stable at 3 days follow up, no
reported death or significant adverse events duringthe
study period.
Conclusion: In contrast to the current recommenda-
tions, continuing use of metformin duringcontrast expo-
sure in high risk population was found to be safe and
not associated with clinically significant lactic acidosis.
http://dx.doi:10.1016/j.jsha.2013.03.028
Use of combination of mitral clip and CGMP-
specific phosphodiesterase type 5 inhibitor as
bridge for cardiac transplantation
Ali Almasood, Hatem Khairallah, Aijaz Shah,
Moheeb Alabdallah, Mohamed Alotaibi,
Abdulrahman Al-Moghairi
Introduction: Severe mitral regurgitation (MR) and
severe pulmonary hypertension (PH) are common conse-
quence of advanced end stage heart failure (HF). Cardiac
transplantation is the only available treatment modality
with reasonable long term outcome for end stage HF.
Presence of severe resistant PH could preclude trans-
plantation. We reported two cases with end stage heart
failure and NYHA class III, who have been initially
turned down from cardiac transplantation because of
severe PH, and we managed to bridge them with mitral
clip and Sildenafil to be transplant eligible. Description
of the cases.
Case 1: First patient is 50 years old gentleman, who is
known to have ischemic cardiomyopathy, ejection frac-
tion (EF) of 15%, and severe MR, with significant func-
tional limitation (NYHA class III) despite of maximum
medical therapy. His pulmonary arterial systolic pressure
(PASP) was 80 mmHg, TPG = 30 mmHg, pulmonary cap-
illary wedge pressure (PCWP) = 33. After full evaluation
he underwent successful deployment of mitral clip and
started on seldanifl 25 mg three times daily, hoping this
will lower the PASP to an acceptable level, to allowlisting
for cardiac transplantation. Echocardiographic assess-
ment after one month of treatment showed that esti-
mated PASP of 40 mmHg.
Case 2: Second patient is 75 y old, who is known to
have ischemic cardiomyopathy, status post three vessels
angioplasty, with EF of 25%, and severe MR. He was very
symptomatic despite maximum medical therapy. He was
deemed not suitable for cardiac transplantation, because
of severe pulmonary hypertension; PASP = 85 mmHg,
mean PA = 59 mmHg, PCWP = 38 mmHg. He underwent
successful deployment of mitral clip and started on silde-
nafil 25 mg three times daily. At one month follow up
PASP went down to 45 mmHg.
Conclusion: We report for first time a successful use
of mitral clip and sildenafil treatment as a bridge to trans-
plant eligibility, for those who have severe MR and
PHTN secondary to advances heart failure. These
patients may not be otherwise suitable transplant
candidate.
This case report brings a new hope for selected high
risk HF patients, with severe MR and severe PHTN.
http://dx.doi:10.1016/j.jsha.2013.03.029
Management of multiple ventricular septal defec-
ts: Evolution of surgical technique
Adel Ragheb, Seifeldin Bashir, Al Otay
Abdulmajeed, Yahia Alfaraidi, Howida
Alqathamy, Roberto M. Di Donato
Background: Residual ventricular septal defects
(VSDs), ventricular and septal dysfunction and heart
block are frequent complications in surgical management
of multiple VSDs (Swiss cheese heart). The technique
with the lowest risk of morbidity and mortality has still
to be identified.
Methods: Between January 200 and September 2012,
45 patients with a median age of 4.1 years (2 months to 15
years) underwent surgical closure of multiple VSDs. In 22
cases there were associated lesions. Two-stage repair, i.e.
pulmonary artery banding (PAB) followed by VSDs clo-
sure using different techniques, was adopted in 29 cases
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